| Objective:By observing the effect of 40 mg atorvastatin on bilateral vertebral/basal artery with severe stenosis/occlusion,we can obtain the related data of 40 mg atorvastatin's effect on end point events of this group and know about the safety of 40 mg atorvastatin for Hebei people.At last,we can assess the benefits and risks of moderate dose of atorvastatin.Methods:From December 2015 to July 2017,49 patients diagnosed as bilateral vertebral /basal arterial with severe stenosis/occlusion by head MRA/CTA/DSA were collected in neurology department of a three-nail hospital in Hebei province.All the patients were given basic secondary prevention drugs and atorvastatin for secondary prevention.According to the daily dose of atorvastatin,those patients were divided into two groups: 40 mg as observation group,and 20 mg as control group.Compare the incidence of the first?third?sixth month's endpoint events,and the first?third month's adverse reactions,such as liver and muscle enzyme levels.Applied SPSS19.0 for statistical analys is on date of two groups.Results:1.General informationThe age?gender?NISS score of the two groups were not statistically different(P>0.05).2.The comparison of the incidences of endpoint events in two groupsThere was no statistically s ignificant difference in the incidences of endpoints of the two groups in the first,third and sixth months(P>0.05).3.There was not only correlation but also linear relationship between time and endpoint events occurrence.4.The comparison of the rates of adverse events in two groupsThe incidences of adverse events of two groups in the first,third months were not statistically different(P>0.05).Conclusion:1.it is not considered that 40 mg atorvastatin can reduce the incidence of end-point events in patients with bilateral vertebral /basal artery stenosis /occlusion when it is matched with 20 mg group.2.40 mg atorvastatin is of high safety in Hebei population. |
PDF Full Text Request